胃肠间质瘤患者中[68Ga]Ga-NOTA-RM26与[18F]FDG PET/CT的头对头比较:一项前瞻性研究
这项前瞻性研究纳入30例疑似或确诊胃肠间质瘤(GIST)患者,均行[68Ga]Ga-NOTA-RM26与[18F]FDG PET/CT检查。18个GIST病灶中,[68Ga]Ga-NOTA-RM26 PET的SUVmax均值显著高于[18F]FDG PET(17.07 ± 19.57 vs. 2.28 ± 1.65;P < 0.01),肿瘤检出率也更高(88.9% vs. 50%;P < 0.01)。作者认为[68Ga]Ga-NOTA-RM26 PET/CT是检测GIST有前景且有效的影像方法。
要点
- [68Ga]Ga-NOTA-RM26 PET/CT对GIST的检出率高于[18F]FDG PET/CT(88.9% vs. 50%;P < 0.01)。
- 18个GIST中[68Ga]Ga-NOTA-RM26的SUVmax均值高于[18F]FDG(17.07 ± 19.57 vs. 2.28 ± 1.65;P < 0.01)。
- 以SUVmax cutoff值6.0诊断GIST的灵敏度为72%、特异度为85.7%。
核心结论
- 与[18F]FDG PET/CT相比,[68Ga]Ga-NOTA-RM26 PET/CT是检测GIST有前景且有效的影像方法。
研究设计与样本
- 前瞻性研究,经机构审查委员会批准并取得知情同意,纳入30例基于腹部CT或胃镜怀疑或确诊GIST的患者。
- 所有患者均接受[68Ga]Ga-NOTA-RM26与[18F]FDG PET/CT扫描,并收集病理及其他患者信息。
主要发现
- 患者中未观察到放射性药物相关不良事件。
- 16例患者的18个病灶诊断为GIST,3例诊断为神经鞘瘤,4例诊断为平滑肌瘤。
- 18个GIST中,[68Ga]Ga-NOTA-RM26 PET的SUVmax均值显著高于[18F]FDG PET(17.07 ± 19.57 vs. 2.28 ± 1.65;P < 0.01)。
- [68Ga]Ga-NOTA-RM26 PET/CT的肿瘤检出率高于[18F]FDG PET/CT(88.9% vs. 50%;P < 0.01)。
- GIST中[68Ga]Ga-NOTA-RM26的摄取显著高于其他2种良性肿瘤(平滑肌瘤或神经鞘瘤)(17.07 ± 19.57 vs. 4.23 ± 1.77;P = 0.014)。
关键数值与推荐
- 以SUVmax cutoff值6.0,[68Ga]Ga-NOTA-RM26 PET/CT诊断GIST的灵敏度为72%,特异度为85.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastrointestinal stromal tumors (GISTs) are the most common stromal tumors in the gastrointestinal tract. This study was designed to evaluate a gastrin-releasing peptide receptor antagonist PET tracer, [68Ga]Ga-NOTA-RM26, and compare it with [18F]FDG PET/CT in the assessment of patients with GISTs. Methods: With institutional review board approval and informed consent, 30 patients with suspected or proven GISTs based on abdominal CT or gastroscopy were recruited. All patients underwent [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT scans. Pathology and other patient information were collected. Results: No radiopharmaceutical-related adverse events were observed in the patients. In total, 18 lesions in 16 patients were diagnosed as GIST, 3 patients were diagnosed with schwannoma, and 4 patients were diagnosed with leiomyoma. In 18 GISTs, the mean SUVmax of [68Ga]Ga-NOTA-RM26 PET was significantly higher than that of [18F]FDG PET (17.07 ± 19.57 vs. 2.28 ± 1.65; P < 0.01), and [68Ga]Ga-NOTA-RM26 PET/CT had a higher tumor detection rate than did [18F]FDG PET/CT (88.9% vs. 50%; P < 0.01). The uptake of [68Ga]Ga-NOTA-RM26 in GISTs was significantly higher than that in 2 other benign tumors (leiomyoma or schwannoma) (17.07 ± 19.57 vs. 4.23 ± 1.77; P = 0.014). With the SUVmax cutoff value of 6.0, the sensitivity of 68Ga-NOTA-RM26 PET/CT in diagnosing GISTs is 72% and the specificity is 85.7%. Conclusion: Compared with [18F]FDG PET/CT, [68Ga]Ga-NOTA-RM26 PET/CT is a promising and effective imaging modality for the detection of GISTs.
引用
- Wang R, Kang W, Liu Z, et al. Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study. J Nucl Med. 2025. PMID: 39448271. doi:10.2967/jnumed.124.267810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。